Pharmaceuticals News and Research

RSS

t2c001 product obtains certificate under EMA regulations for ATMPs

t2cure GmbH, a biopharmaceutical company developing and marketing stem cell-based regenerative therapies, announced today that the quality of its lead product t2c001 has been certified by the European Medicines Agency.

25 May 2010

Family of EPA-registered disinfecting products to be launched

An innovative family of EPA-registered disinfecting products will be launched through a new direct selling company, it was announced today.

25 May 2010

LEO Pharma implements Cegedim Dendrite's Mobile Intelligence CRM solution in 6 Asia-Pacific countries

Cegedim Dendrite today announced that LEO Pharma has implemented Mobile Intelligence™, Cegedim Dendrite's flagship Customer Relationship Management (CRM) solution using a Software as a Service (SaaS) delivery model, in six countries in the Asia-Pacific region. LEO Pharma is a global pharmaceutical company specializing in dermatology and critical care and Cegedim Dendrite is the world's leading provider of Pharmaceutical CRM solutions with a 35 percent global market share.

25 May 2010

DAPT Study expands into seven countries in the EU: HCRI

The Harvard Clinical Research Institute announced today that the DAPT Study has expanded into seven countries in the European Union. John Irving, MBChB, MRCP, M.D., consultant cardiologist at Ninewells Hospital in Dundee, United Kingdom, was the first European investigator to enroll patients into the study.

25 May 2010

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX®) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).

25 May 2010

ADDF provides $248,000 grant to ALSP to allow its lead drug candidate towards clinical trials

The Alzheimer's Drug Discovery Foundation announced today that it is providing a grant of $248,000 to American Life Science Pharmaceuticals, Inc. to allow for manufacture of its lead drug candidate to be used in preclinical toxicology testing in preparation for entering Phase I clinical trials early in 2011.

25 May 2010

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Synta Pharmaceuticals Corp. today announced that clinical activity seen in the first stage of its trial for STA-9090 in Stage IIIB and Stage IV patients with non-small cell lung cancer, support advancing to the second stage of the trial. This result was achieved in the first pre-defined patient cohort to complete enrollment.

25 May 2010

FDA approves Watson Pharmaceuticals' generic version of VALTREX tablets

Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application for Valacyclovir Hydrochloride tablets, USP, in the 500 and 1000 mg strengths, the generic equivalent to GlaxoSmithKline, LLC's VALTREX tablets.

25 May 2010

New HPLC-Chip introduced to address N-glycan analysis in biopharmaceutical market

Agilent Technologies Inc. today introduced a new HPLC-Chip to address N-glycan analysis in the emerging biopharmaceutical market.

25 May 2010

Elite Pharmaceuticals acquires hydromorphone hydrochloride tablets from Mikah Pharma

Elite Pharmaceuticals, Inc. announced today the acquisition of a currently approved Abbreviated New Drug Application (ANDA) for hydromorphone hydrochloride 8 mg tablets from Mikah Pharma LLC. The hydromorphone hydrochloride tablets are the generic equivalent of Dilaudid® 8 mg.

25 May 2010

66% of patients with schizophrenia have extreme trust in their psychiatrists: New survey

According to a new survey sponsored by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, 80 percent of patients with schizophrenia, a chronic, severe and disabling brain disorder, say their psychiatrists do well or very well in treating them with courtesy and respect. This positive relationship is particularly important in treating schizophrenia as patients and psychiatrists must work closely together to determine appropriate treatment plans that will help patients manage their symptoms and reduce their risk of relapse.

24 May 2010

OnePath Gaucher Application available for patients with Type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, today announced the availability of the OnePath Gaucher Application. The first and only application developed specifically for patients in the U.S. with Type 1 Gaucher disease, it is free and ready for download at the iTunes Application store.

24 May 2010

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced plans to submit a Phase III trial design for DAVANAT to the U.S. Food and Drug Administration during the second half of 2010. The Company has added the talent of Peter G. Traber, M.D., to its FDA approval strategy and trial design team.

24 May 2010

Expression Analysis agrees to purchase PacBio RS DNA sequencing system from Pacific Biosciences

Expression Analysis, a leading provider of genomic services for clinical trials and research, announced today that it has agreed to purchase a PacBio RS DNA sequencing system from northern-California based Pacific Biosciences, whose third-generation DNA sequencing technology is expected to revolutionize the field of genetic analysis through the use of single molecule real time detection of biological events.

24 May 2010

China Yongxin Pharmaceuticals first-quarter 2010 revenues increase 16.3% to $10.68M

China Yongxin Pharmaceuticals Inc., one of the leading health products distribution and retail sales companies in China, today announced its financial results for the first quarter ending March 31, 2010.

24 May 2010

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Salix Pharmaceuticals, Ltd. today announced the availability of Xifaxan (rifaximin) 550 mg tablets for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years of age or older. Those HE patients may now fill their Xifaxan 550 mg prescriptions in U.S. pharmacies and should speak with their doctors about this important treatment option.

24 May 2010

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.

24 May 2010

Ortho-McNeil Pharmaceutical pleads guilty for promoting epilepsy drug Topamax for psychiatric use

Ortho-McNeil Pharmaceutical LLC, a subsidiary of Johnson & Johnson, pled guilty today in U.S. District Court in Boston to one count of misdemeanor violation of the Food, Drug & Cosmetic Act for illegally promoting its epilepsy drug Topamax for uses that were not approved by the FDA. The company was also sentenced at today's hearing.

24 May 2010

Majority parents feel they should decide on vaccination for their children, not the government : Harris Interactive poll

A new Harris Interactive poll shows a majority of American parents believe they, rather than the government, should have the final say in which vaccines their children receive.

24 May 2010

NCC receives $25,000 grant award from Hospira Foundation to support pharmaceutical relief program

The National Cancer Coalition is pleased to announce that it recently received a $25,000 grant award from the Hospira Foundation, the philanthropic arm of Hospira, Inc., to support its pharmaceutical relief program within the Dominican Republic. NCC is seeking to significantly increase the levels of medical resources that it provides to the public hospitals of the Dominican Republic in an effort to more fully treat the country's underserved patients, and this grant will contribute toward achieving that goal.

24 May 2010

Pharmaceuticals News and Research

t2c001 product obtains certificate under EMA regulations for ATMPs

Family of EPA-registered disinfecting products to be launched

LEO Pharma implements Cegedim Dendrite's Mobile Intelligence CRM solution in 6 Asia-Pacific countries

DAPT Study expands into seven countries in the EU: HCRI

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

ADDF provides $248,000 grant to ALSP to allow its lead drug candidate towards clinical trials

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

FDA approves Watson Pharmaceuticals' generic version of VALTREX tablets

New HPLC-Chip introduced to address N-glycan analysis in biopharmaceutical market

Elite Pharmaceuticals acquires hydromorphone hydrochloride tablets from Mikah Pharma

66% of patients with schizophrenia have extreme trust in their psychiatrists: New survey

OnePath Gaucher Application available for patients with Type 1 Gaucher disease

Pro-Pharmaceuticals plans to submit Phase III trial design for DAVANAT to FDA

Expression Analysis agrees to purchase PacBio RS DNA sequencing system from Pacific Biosciences

China Yongxin Pharmaceuticals first-quarter 2010 revenues increase 16.3% to $10.68M

Salix Pharmaceuticals announces availability of Xifaxan tablets for reducing risk of overt HE recurrence

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Ortho-McNeil Pharmaceutical pleads guilty for promoting epilepsy drug Topamax for psychiatric use

Majority parents feel they should decide on vaccination for their children, not the government : Harris Interactive poll

NCC receives $25,000 grant award from Hospira Foundation to support pharmaceutical relief program

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence